利妥昔单抗成功治疗胸腺切除术后纯红细胞发育不全1例。

IF 0.7 Q4 ONCOLOGY
Case Reports in Oncology Pub Date : 2025-01-14 eCollection Date: 2025-01-01 DOI:10.1159/000542915
Mohammed Abdulgayoom, Ibrahim Ganwo, Fateen Ata, Haval Surchi, Ussama Al-Homsi, Honar Cherif
{"title":"利妥昔单抗成功治疗胸腺切除术后纯红细胞发育不全1例。","authors":"Mohammed Abdulgayoom, Ibrahim Ganwo, Fateen Ata, Haval Surchi, Ussama Al-Homsi, Honar Cherif","doi":"10.1159/000542915","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pure red cell aplasia (PRCA) is a rare cause of anemia characterized by decreased red blood cell production, often associated with thymomas. While thymectomy is commonly performed to treat thymoma-associated PRCA, the development of PRCA post-thymectomy is less understood.</p><p><strong>Case presentation: </strong>We present a case of a 25-year-old woman who developed PRCA and autoimmune diabetes mellitus (DM) following radical thymectomy for malignant thymoma. Initial treatment with prednisolone showed minimal improvement, leading to the inclusion of rituximab. This combination resulted in a significant increase in reticulocyte counts and transfusion independence.</p><p><strong>Discussion: </strong>This case highlights the potential for PRCA to develop after thymectomy and the challenges of treating PRCA in the context of additional conditions like autoimmune DM. While immunosuppressive therapies such as cyclosporin A and corticosteroids are standard, their side effects necessitated exploring alternative treatments. Rituximab proved effective and was well-tolerated, suggesting its potential as a primary option in similar cases.</p><p><strong>Conclusion: </strong>This case illustrates the occurrence of PRCA after thymectomy and highlights rituximab's effectiveness as a treatment option, offering a viable alternative to standard therapies in managing this complex condition.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"100-106"},"PeriodicalIF":0.7000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731903/pdf/","citationCount":"0","resultStr":"{\"title\":\"Successful Management of Post-Thymectomy Pure Red Cell Aplasia with Rituximab: A Case Report.\",\"authors\":\"Mohammed Abdulgayoom, Ibrahim Ganwo, Fateen Ata, Haval Surchi, Ussama Al-Homsi, Honar Cherif\",\"doi\":\"10.1159/000542915\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Pure red cell aplasia (PRCA) is a rare cause of anemia characterized by decreased red blood cell production, often associated with thymomas. While thymectomy is commonly performed to treat thymoma-associated PRCA, the development of PRCA post-thymectomy is less understood.</p><p><strong>Case presentation: </strong>We present a case of a 25-year-old woman who developed PRCA and autoimmune diabetes mellitus (DM) following radical thymectomy for malignant thymoma. Initial treatment with prednisolone showed minimal improvement, leading to the inclusion of rituximab. This combination resulted in a significant increase in reticulocyte counts and transfusion independence.</p><p><strong>Discussion: </strong>This case highlights the potential for PRCA to develop after thymectomy and the challenges of treating PRCA in the context of additional conditions like autoimmune DM. While immunosuppressive therapies such as cyclosporin A and corticosteroids are standard, their side effects necessitated exploring alternative treatments. Rituximab proved effective and was well-tolerated, suggesting its potential as a primary option in similar cases.</p><p><strong>Conclusion: </strong>This case illustrates the occurrence of PRCA after thymectomy and highlights rituximab's effectiveness as a treatment option, offering a viable alternative to standard therapies in managing this complex condition.</p>\",\"PeriodicalId\":9625,\"journal\":{\"name\":\"Case Reports in Oncology\",\"volume\":\"18 1\",\"pages\":\"100-106\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-01-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731903/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000542915\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000542915","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:纯红细胞再生不全(PRCA)是一种罕见的贫血原因,其特征是红细胞生成减少,通常与胸腺瘤有关。虽然胸腺切除术通常用于治疗胸腺瘤相关的PRCA,但胸腺切除术后PRCA的发展尚不清楚。病例介绍:我们报告了一例25岁的女性,她在恶性胸腺瘤根治性胸腺切除术后发展为PRCA和自身免疫性糖尿病(DM)。最初用强的松龙治疗显示改善甚微,导致纳入利妥昔单抗。这种组合导致网织红细胞计数和输血独立性显著增加。讨论:该病例强调了胸腺切除术后发生PRCA的可能性,以及在自身免疫性糖尿病等其他疾病的背景下治疗PRCA的挑战。虽然免疫抑制疗法如环孢素A和皮质类固醇是标准的,但它们的副作用需要探索替代疗法。利妥昔单抗被证明有效且耐受性良好,这表明它有可能成为类似病例的主要选择。结论:该病例说明了胸腺切除术后PRCA的发生,并强调了利妥昔单抗作为治疗选择的有效性,为治疗这种复杂的疾病提供了标准治疗的可行替代方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Successful Management of Post-Thymectomy Pure Red Cell Aplasia with Rituximab: A Case Report.

Background: Pure red cell aplasia (PRCA) is a rare cause of anemia characterized by decreased red blood cell production, often associated with thymomas. While thymectomy is commonly performed to treat thymoma-associated PRCA, the development of PRCA post-thymectomy is less understood.

Case presentation: We present a case of a 25-year-old woman who developed PRCA and autoimmune diabetes mellitus (DM) following radical thymectomy for malignant thymoma. Initial treatment with prednisolone showed minimal improvement, leading to the inclusion of rituximab. This combination resulted in a significant increase in reticulocyte counts and transfusion independence.

Discussion: This case highlights the potential for PRCA to develop after thymectomy and the challenges of treating PRCA in the context of additional conditions like autoimmune DM. While immunosuppressive therapies such as cyclosporin A and corticosteroids are standard, their side effects necessitated exploring alternative treatments. Rituximab proved effective and was well-tolerated, suggesting its potential as a primary option in similar cases.

Conclusion: This case illustrates the occurrence of PRCA after thymectomy and highlights rituximab's effectiveness as a treatment option, offering a viable alternative to standard therapies in managing this complex condition.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.40
自引率
12.50%
发文量
151
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信